Homeopathy 2024; 113(01): 016-024
DOI: 10.1055/s-0043-1770339
Original Research Article

Antiviral Activity of Cinchona officinalis, a Homeopathic Medicine, against COVID-19

Authors

  • Somasundaram Arumugam

    1   Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Chunilal Bhawan, Kolkata, West Bengal, India
  • Kumaravel Vadivel

    2   Department of Pathology and Microbiology, National Institute of Homeopathy (NIH), Kolkata, West Bengal, India
  • Devendra Kumar Dhaked

    3   Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), Chunilal Bhawan, Kolkata, West Bengal, India
  • Vani Sai Prasanna

    1   Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Chunilal Bhawan, Kolkata, West Bengal, India
  • Manoj Limbraj Yellurkar

    1   Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Chunilal Bhawan, Kolkata, West Bengal, India
  • Pamelika Das

    1   Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Chunilal Bhawan, Kolkata, West Bengal, India
  • Raja Manoharan

    4   Department of Homeopathic Pharmacy, National Institute of Homeopathy (NIH), Kolkata, West Bengal, India
  • Austin Jose Thomas

    5   National Institute of Homeopathy (NIH), Kolkata, West Bengal, India
  • Lalith Singh

    5   National Institute of Homeopathy (NIH), Kolkata, West Bengal, India
  • Subhas Singh

    6   Department of Organon of Medicine, National Institute of Homeopathy (NIH), Kolkata, West Bengal, India
  • Ravichandiran Velayutham

    7   National Institute of Pharmaceutical Education and Research (NIPER), Chunilal Bhawan, 168 Maniktala Main Road, Kolkata, West Bengal, India
Preview

Abstract

Background Coronavirus disease 2019 (COVID-19) is a potentially fatal disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several studies have shown that hydroxychloroquine (HCQ) significantly inhibits SARS-CoV-2 infections in vitro.

Objective Since the phytoconstituents of Cinchona officinalis (CO) are similar to those of HCQ, the objective of this study was to test the antiviral potential of different homeopathic formulations of CO.

Methods An analysis of the molecular composition of CO was carried out using ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry, followed by a detailed docking study. The constituents of CO were docked against various targets of SARS-CoV-2, and the binding potential of the phytoconstituents was compared and quantified. The ligand with the lowest Glide docking score is considered to have the best binding affinity. The cytotoxicity of several homeopathic formulations, including CO mother tincture (CO-MT), was also checked on VeroE6 cells. A known antiviral, remdesivir, was used as a positive control for the in vitro assays to evaluate the effects of CO-MT against SARS-CoV-2-infected VeroE6 cells.

Results Molecular docking studies showed that constituents of CO exhibited binding potential to various targets of SARS-CoV-2, including Mpro, PLpro, RdRp, nucleocapsid protein, ACE2 (in host) and spike protein. Quinoline, one of the constituents of CO, can potentially bind the spike protein of SARS-CoV-2. Quinic acid showed better binding capabilities with Mpro, PLpro RdRp, nucleocapsid protein and ACE2 (allosteric site) than other constituents. Quinidine exhibited better binding to ACE2. Compared to HCQ, other phytoconstituents of CO had the equivalent potential to bind the RNA-dependent RNA polymerase, nucleocapsid protein, Mpro, PLpro and spike protein of SARS-CoV-2. In vitro assays showed that homeopathic CO-MT was not cytotoxic and that CO-MT and remdesivir respectively caused 89% and 99% inhibition of SARS-CoV-2 infection in VeroE6 cells.

Conclusion Based on this in silico and in vitro evidence, we propose CO-MT as a promising antiviral medicine candidate for treating COVID-19. In vivo investigation is required to clarify the therapeutic potential of CO-MT in COVID-19.



Publication History

Received: 06 February 2023

Accepted: 20 April 2023

Article published online:
06 September 2023

© 2023. Faculty of Homeopathy. This article is published by Thieme.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany